Levels of Trimethylamine N-Oxide Remain Elevated Long Term After Left Ventricular Assist Device and Heart Transplantation and Are Independent From Measures of Inflammation and Gut Dysbiosis
暂无分享,去创建一个
G. Sayer | N. Uriel | R. Nandakumar | Y. Naka | R. Demmer | M. Farr | S. Mohan | P. Colombo | B. Cagliostro | M. Yuzefpolskaya | K. Takeda | A. Pinsino | G. Mondellini | Duygu Onat | A. Javaid | L. Braghieri | A. Kim | B. Bohn
[1] S. Hazen,et al. Targeted Inhibition of Gut Microbial Trimethylamine N-Oxide Production Reduces Renal Tubulointerstitial Fibrosis and Functional Impairment in a Murine Model of Chronic Kidney Disease , 2020, Arteriosclerosis, thrombosis, and vascular biology.
[2] R. Nandakumar,et al. Gut microbiota, endotoxemia, inflammation, and oxidative stress in patients with heart failure, left ventricular assist device, and transplant. , 2020, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[3] R. Nandakumar,et al. Plasma Trimethylamine-N-oxide and impaired glucose regulation: Results from The Oral Infections, Glucose Intolerance and Insulin Resistance Study (ORIGINS) , 2020, PloS one.
[4] A. Masoumi,et al. Cystatin C- Versus Creatinine-Based Assessment of Renal Function and Prediction of Early Outcomes Among Patients With a Left Ventricular Assist Device , 2020, Circulation. Heart failure.
[5] D. Jacobs,et al. Association Between Nitrate‐Reducing Oral Bacteria and Cardiometabolic Outcomes: Results From ORIGINS , 2019, Journal of the American Heart Association.
[6] Akshay S. Desai,et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. , 2019, The New England journal of medicine.
[7] J. Ferguson,et al. The Gut Microbiome and Response to Cardiovascular Drugs. , 2019, Circulation. Genomic and precision medicine.
[8] G. Dellgren,et al. The carnitine-butyrobetaine-TMAO pathway after cardiac transplant: Impact on cardiac allograft vasculopathy and acute rejection. , 2019, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[9] Li Song,et al. Plasma Trimethylamine N-Oxide as a Novel Biomarker for Plaque Rupture in Patients With ST-Segment–Elevation Myocardial Infarction , 2019, Circulation. Cardiovascular interventions.
[10] Donald J L Jones,et al. Association with outcomes and response to treatment of trimethylamine N‐oxide in heart failure: results from BIOSTAT‐CHF , 2018, European journal of heart failure.
[11] Paul Theodor Pyl,et al. Recovery of gut microbiota of healthy adults following antibiotic exposure , 2018, Nature Microbiology.
[12] Michael R. Taylor,et al. An intact microbiota is required for the gastrointestinal toxicity of the immunosuppressant mycophenolate mofetil. , 2018, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.
[13] S. Hazen,et al. Gut Microbiota–Dependent Trimethylamine N-Oxide Predicts Risk of Cardiovascular Events in Patients With Stroke and Is Related to Proinflammatory Monocytes , 2018, Arteriosclerosis, thrombosis, and vascular biology.
[14] T. Ueland,et al. Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. , 2018, Journal of the American College of Cardiology.
[15] M. Kahn,et al. Reporting Data Quality Assessment Results: Identifying Individual and Organizational Barriers and Solutions , 2017, EGEMS.
[16] M. Bell,et al. Superiority of Serum Cystatin C Over Creatinine in Prediction of Long-Term Prognosis at Discharge From ICU , 2017, Critical care medicine.
[17] Patrick B. Ryan,et al. A Comparison of Data Quality Assessment Checks in Six Data Sharing Networks , 2017, EGEMS.
[18] D. Pieper,et al. Uncovering the trimethylamine-producing bacteria of the human gut microbiota , 2017, Microbiome.
[19] W. Lieb,et al. Heart failure is associated with depletion of core intestinal microbiota , 2017, ESC heart failure.
[20] L. Räber,et al. Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors , 2017, European heart journal.
[21] Y. Naka,et al. Changes in End-Organ Function in Patients With Prolonged Continuous-Flow Left Ventricular Assist Device Support. , 2017, The Annals of thoracic surgery.
[22] Brian J. Bennett,et al. Microbiota‐Dependent Metabolite Trimethylamine N‐Oxide and Coronary Artery Calcium in the Coronary Artery Risk Development in Young Adults Study (CARDIA) , 2016, Journal of the American Heart Association.
[23] Stanley L. Hazen,et al. Plasma Trimethylamine N-Oxide, a Gut Microbe-Generated Phosphatidylcholine Metabolite, Is Associated With Atherosclerotic Burden. , 2016, Journal of the American College of Cardiology.
[24] P. Stenvinkel,et al. Serum Trimethylamine-N-Oxide Is Strongly Related to Renal Function and Predicts Outcome in Chronic Kidney Disease , 2016, PloS one.
[25] S. Bhushan,et al. Choline Diet and Its Gut Microbe–Derived Metabolite, Trimethylamine N-Oxide, Exacerbate Pressure Overload–Induced Heart Failure , 2016, Circulation. Heart failure.
[26] T. Karlsen,et al. Microbiota‐dependent metabolite trimethylamine‐N‐oxide is associated with disease severity and survival of patients with chronic heart failure , 2015, Journal of internal medicine.
[27] Zeneng Wang,et al. Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. , 2015, Journal of cardiac failure.
[28] S. Hazen,et al. Gut Microbiota-Dependent Trimethylamine N-Oxide (TMAO) Pathway Contributes to Both Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease , 2015, Circulation research.
[29] S. Hazen,et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. , 2014, Journal of the American College of Cardiology.
[30] Akshay S. Desai,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.
[31] S. Hazen,et al. Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. , 2014, European heart journal.
[32] S. Kimmel,et al. Prevalence and Prognostic Importance of Changes in Renal Function After Mechanical Circulatory Support , 2014, Circulation. Heart failure.
[33] I. Piña,et al. Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.
[34] S. Hazen,et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. , 2013, The New England journal of medicine.
[35] K. Hatori,et al. Trimethylamine N-oxide suppresses the activity of the actomyosin motor. , 2012, Biochimica et biophysica acta.
[36] S. Hazen,et al. Cystatin C Identifies Patients With Stable Chronic Heart Failure at Increased Risk for Adverse Cardiovascular Events , 2012, Circulation. Heart failure.
[37] Harold I Feldman,et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. , 2012, The New England journal of medicine.
[38] Katherine H. Huang,et al. Structure, Function and Diversity of the Healthy Human Microbiome , 2012, Nature.
[39] G. Beck,et al. Changes in dietary protein intake has no effect on serum cystatin C levels independent of the glomerular filtration rate. , 2011, Kidney international.
[40] D. Relman,et al. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation , 2010, Proceedings of the National Academy of Sciences.
[41] M. Crespo-Leiro,et al. Prevalence and severity of renal dysfunction among 1062 heart transplant patients according to criteria based on serum creatinine and estimated glomerular filtration rate: results from the CAPRI study , 2010, Clinical transplantation.
[42] Jeroen J. Bax,et al. Characteristics of heart failure patients associated with good and poor response to cardiac resynchronization therapy: a PROSPECT (Predictors of Response to CRT) sub-analysis. , 2009, European heart journal.
[43] P. Poole‐Wilson,et al. Altered intestinal function in patients with chronic heart failure. , 2007, Journal of the American College of Cardiology.
[44] R. Milne,et al. Oral L-carnitine: metabolite formation and hemodialysis. , 2006, Current drug metabolism.
[45] Tom Greene,et al. Using Standardized Serum Creatinine Values in the Modification of Diet in Renal Disease Study Equation for Estimating Glomerular Filtration Rate , 2006, Annals of Internal Medicine.
[46] M. Nieminen,et al. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. , 2006, European heart journal.
[47] T. Sauerbruch,et al. Calculation of glomerular filtration rate based on cystatin C in cirrhotic patients. , 2006, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[48] Christine A. White,et al. Estimating glomerular filtration rate in kidney transplantation: a comparison between serum creatinine and cystatin C-based methods. , 2005, Journal of the American Society of Nephrology : JASN.
[49] B. Psaty,et al. Cystatin-C and mortality in elderly persons with heart failure. , 2005, Journal of the American College of Cardiology.
[50] F. Waagstein,et al. Predictors and evolution of renal function during 9 years following heart transplantation. , 2000, Journal of the American Society of Nephrology : JASN.
[51] P J Sadler,et al. Nuclear magnetic resonance studies of blood plasma and urine from subjects with chronic renal failure: identification of trimethylamine-N-oxide. , 1991, Biochimica et biophysica acta.
[52] H. Fillit,et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. , 1990, The New England journal of medicine.
[53] R. Califf,et al. Comparative assessment of short-term adverse events in acute heart failure with cystatin C and other estimates of renal function: results from the ASCEND-HF trial. , 2015, JACC. Heart failure.